Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001240795 | SCV001413769 | uncertain significance | Bardet-Biedl syndrome | 2024-11-11 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 386 of the BBS2 protein (p.Thr386Met). This variant is present in population databases (rs138314289, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 966180). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BBS2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002484320 | SCV002785139 | uncertain significance | Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 | 2022-04-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001277877 | SCV001464856 | likely benign | Bardet-Biedl syndrome 2 | 2020-09-03 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004538502 | SCV004733423 | likely benign | BBS2-related disorder | 2020-07-10 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |